Drug Profile
PSMA VRP
Alternative Names: PSMA-VRPLatest Information Update: 17 Feb 2021
Price :
$50
*
At a glance
- Originator Progenics Pharmaceuticals
- Class Antineoplastics; Cancer vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 17 Feb 2021 Discontinued - Phase-II for Prostate cancer in USA (SC) Progenics Pharmaceuticals pipeline, February 2021
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 07 May 2018 Phase-II clinical trials in Prostate cancer in USA (SC) (AlphaVax pipeline, May 2018)